Hemp

Hemp Regulation Bill Draws Pushback From Unlikely Coalition

mm
Add MyCannabis.com to your preferred sources on Google

A Kentucky Republican is about to file legislation that would replace next November’s scheduled crackdown on most hemp-derived products with a federal regulatory framework — and the bill is drawing opposition from an unusual alignment of distilled spirits producers, state-licensed marijuana businesses, and anti-cannabis prohibition groups.

Rep. Andy Barr is set to introduce the Lawful Hemp Protection Act, according to hemp industry representatives who have seen draft versions of the bill. The proposal would establish FDA oversight for hemp-derived consumer products, route excise taxes through the Treasury Department’s Alcohol and Tobacco Tax and Trade Bureau, set a 21-and-older age threshold for all consumable hemp products, and run distribution of hemp beverages through a three-tier wholesale model modeled on the alcohol industry. It would also ban synthetic cannabinoids and restrict the market to American-grown hemp.

The November 2026 deadline the bill is designed to preempt is hard federal law. Spending legislation enacted on November 12, 2025 — referenced directly in President Trump’s December 18, 2025 executive order on hemp and CBD access — redefined legal hemp to exclude final consumer products containing more than 0.4 milligrams of total THC per container, a threshold low enough to render the vast majority of hemp-derived gummies, beverages, vapes, and oils currently sold in the United States federally unlawful when the law takes effect. The total-THC cap sweeps in not just intoxicating delta-8 products but also many full-spectrum CBD products that carry trace THC levels. What the 2026 definition change means in practice for current hemp products is covered in earlier reporting here.

Barr has framed the issue as an agricultural emergency as much as a consumer one. Central Kentucky farmers who legally grew hemp in 2025 are sitting on crop they can’t sell into a market with no legal future. Barr is also running for the Senate seat being vacated by Mitch McConnell, who authored the hemp ban language in last year’s spending package.

Three opposition camps, one strange front

The opposition Barr has encountered doesn’t come from a single direction, which complicates the legislative path considerably. Producers of distilled spirits have a direct commercial stake in keeping hemp-derived THC beverages out of mainstream retail: low-dose hemp drinks compete for the same shelf space as beer and wine. Barr has acknowledged this as an “understandable concern about competition” while arguing that a level regulatory playing field — the same age verification, tax, and distribution requirements that apply to alcohol — is the right answer rather than exclusion.

The wholesale tier of the alcohol industry is more receptive. A three-tier distribution system gives alcohol wholesalers a built-in role in the hemp beverage supply chain, and Barr’s framework builds that in. The distilled spirits producer and wholesale interests don’t necessarily align: producers want hemp kept off mainstream shelves; distributors want to move whatever product clears regulatory review.

State-licensed marijuana dispensaries represent the second opposition bloc. Their objection isn’t to hemp products on principle — it’s to channel competition. Dispensary operations in adult-use states carry license costs, testing mandates, local zoning restrictions, and compliance overhead that hemp-derived THC products sold at convenience stores or direct-to-consumer online do not. Barr has said this sector would push the entire hemp market into dispensary-only channels, a position he considers inappropriate for what is legally a distinct, agricultural-origin product category.

The third bloc — traditional prohibition groups — requires less unpacking. They oppose the hemp market on principle, viewing any regulatory framework as acceptance of products they consider harmful. Barr has suggested this camp may not be persuadable.

White House alignment and the path forward

The Trump administration has been in substantive dialogue with Barr’s office on the hemp definition question. The December 18, 2025 executive order directed senior White House officials to work with Congress to update the statutory definition of final hemp-derived cannabinoid products — specifically to preserve access to full-spectrum CBD while restricting products that pose health risks. More recently, Vince Haley, director of the White House Domestic Policy Council, and James Braid, the president’s assistant for legislative affairs, sent Barr’s office draft legislative text and technical comments responding to the pending bill. The administration’s proposed language has not been made public.

Trump weighed in more directly on April 23, 2026, the same day the Justice Department announced its expedited marijuana rescheduling action. Calling on Congress to act before the November deadline, Trump cited the CBD products that chronic-pain patients and veterans use and linked the hemp question to protecting American farmers.

The House passed the 2026 Farm Bill on April 30, 2026, without any provision addressing the hemp product definition or delaying the ban. A House panel separately directed the DEA earlier this month to focus enforcement on unregulated cannabinoid products — a parallel track that accelerates enforcement rather than resolving the regulatory gap. The Senate has not advanced its own hemp framework legislation.

Barr’s bill has not yet been filed. Hemp industry representatives expect it within the week, though the timeline has already shifted several times as the congressman refined provisions and sought cosponsors. With roughly six months until November 12, 2026, both the legislative clock and the farming calendar are running.

Ava Morales is an AI-generated analyst at MyCannabis.com, covering U.S. cannabis regulation with a focus on state-by-state legalization, medical programs, and consumer compliance. Her work helps readers navigate the fragmented legal landscape governing cannabis access, possession, and use across the United States.

With a structured and explanatory approach, Ava tracks legislative changes, ballot initiatives, and regulatory guidance affecting both medical and recreational cannabis markets. She emphasizes clarity over speculation, distinguishing clearly between enacted law, proposed reforms, and local enforcement realities so readers understand what is permitted in their jurisdiction today.

Articles authored by Ava Morales are AI-generated and reviewed by MyCannabis.com’s editorial team to ensure accuracy, neutrality, and responsible reporting on cannabis laws in regulated U.S. markets.